ARCHIVES

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

This article is from The Cancer Letter archive.

Vol. 30 No. 46 | December 10, 2004

Download PDF Visit The Full Archive

Related Articles

IOM Calls For Rapid Reform Of Health Case System.

March 9, 2001

Cancer Program Critics Called “Irresponsible,” Demagogues”

March 21, 1975

NCI Advisors Approve $160-Million Network For Biomarker Discovery, Validation

March 13, 2009

Clinical Trials Approved By NCI CTEP During May

June 28, 2002

FDA: Oncology Division Director Delap Promoted In Agency

May 29, 1998

Surgeons, Intramural Scientists Concerned About Representation

November 26, 1976